دورية أكاديمية

Concepts and Outcomes of Perioperative Therapy in Stage IA-III Pancreatic Cancer—A Cross-Validation of the National Cancer Database (NCDB) and the German Cancer Registry Group of the Society of German Tumor Centers (GCRG/ADT)

التفاصيل البيبلوغرافية
العنوان: Concepts and Outcomes of Perioperative Therapy in Stage IA-III Pancreatic Cancer—A Cross-Validation of the National Cancer Database (NCDB) and the German Cancer Registry Group of the Society of German Tumor Centers (GCRG/ADT)
المؤلفون: Louisa Bolm, Sergii Zemskov, Maria Zeller, Taisuke Baba, Jorge Roldan, Jon M. Harrison, Natalie Petruch, Hiroki Sato, Ekaterina Petrova, Hryhoriy Lapshyn, Ruediger Braun, Kim C. Honselmann, Richard Hummel, Oleksii Dronov, Alexander V. Kirichenko, Monika Klinkhammer-Schalke, Kees Kleihues-van Tol, Sylke R. Zeissig, Dirk Rades, Tobias Keck, Carlos Fernandez-del Castillo, Ulrich F. Wellner, Rodney E. Wegner
المصدر: Cancers; Volume 14; Issue 4; Pages: 868
بيانات النشر: Multidisciplinary Digital Publishing Institute
سنة النشر: 2022
المجموعة: MDPI Open Access Publishing
مصطلحات موضوعية: pancreatic cancer, perioperative therapy, neoadjuvant therapy, pancreatic surgery
الوصف: (1) Background: The aim of this study is to assess perioperative therapy in stage IA-III pancreatic cancer cross-validating the German Cancer Registry Group of the Society of German Tumor Centers—Network for Care, Quality, and Research in Oncology, Berlin (GCRG/ADT) and the National Cancer Database (NCDB). (2) Methods: Patients with clinical stage IA-III PDAC undergoing surgery alone (OP), neoadjuvant therapy (TX) + surgery (neo + OP), surgery+adjuvantTX (OP + adj) and neoadjuvantTX + surgery + adjuvantTX (neo + OP + adj) were identified. Baseline characteristics, histopathological parameters, and overall survival (OS) were evaluated. (3) Results: 1392 patients from the GCRG/ADT and 29,081 patients from the NCDB were included. Patient selection and strategies of perioperative therapy remained consistent across the registries for stage IA-III pancreatic cancer. Combined neo + OP + adj was associated with prolonged OS as compared to neo + OP alone (17.8 m vs. 21.3 m, p = 0.012) across all stages in the GCRG/ADT registry. Similarly, OS with neo + OP + adj was improved as compared to neo + OP in the NCDB registry (26.4 m vs. 35.4 m, p < 0.001). (4) Conclusion: The cross-validation study demonstrated similar concepts and patient selection criteria of perioperative therapy across clinical stages of PDAC. Neoadjuvant therapy combined with adjuvant therapy is associated with improved overall survival as compared to either therapy alone.
نوع الوثيقة: text
وصف الملف: application/pdf
اللغة: English
العلاقة: https://dx.doi.org/10.3390/cancers14040868Test
DOI: 10.3390/cancers14040868
الإتاحة: https://doi.org/10.3390/cancers14040868Test
حقوق: https://creativecommons.org/licenses/by/4.0Test/
رقم الانضمام: edsbas.307F68AE
قاعدة البيانات: BASE